The RSV shot shortage isn’t just a supply problem
By
On October 13, the drug manufacturer Sanofi made a surprising announcement: Public demand for Beyfortus — the brand name of nirsevimab, the company’s new product aimed at protecting newborns from severe respiratory syncytial virus (RSV) infections — had wildly outpaced supply.
Read full article: https://www.vox.com/2023/10/25/23931321/rsv-beyfortus-nirsevimab-shortage-supply-vfc-vaccines-for-children-respiratory-syncytial-virus